Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (4): 615-620    DOI: 10.12892/ejgo4178.2018
Original Research Previous articles | Next articles
Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites
Li-Yuan Guo1, San-Yuan Zhang2, Chen Chen1, *(), Hao-Xia Zeng1, Feng-Yan Li2, Qiu-Xiang Xu1
1 Department of Gynaecology and Obstetrics, Chaoyang Hospital, Capital Medical University, Beijing, China
2 Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, China
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To observe the clinical efficacy of lentinan combined with cisplatin and paclitaxel in the treatment of ovarian cancer with ascites. Materials and Methods: Two hundred and twelve cases of patients with epithelial ovarian cancer (EOC) and ascites were retrospectively analyzed. Patients were divided into TP (taxinol + platinol) group and TP + lentinan group according to the chemotherapy regimen. Results: The effective rate (CR + PR) in TP group (98 cases) was 31.6% and disease control rate (CR +PR + SD) was 80.6%. The effective rate in TP + lentinan group (114 cases) was 50.9% and the disease control rate was 88.6%, with statistical difference compared with TP group. The control of ascites in TP + lentinan group was better than TP group. The common adverse reactions of chemotherapy in TP + lentinan group was relative mild with reduced incidence. Conclusion: Lentinan combined with chemotherapy could enhance the efficacy of chemotherapy and control of the ascites.
Key words:  Epithelial ovarian cancer      Lentinan      Taxinol      Platinol      Therapeutic effect     
Published:  10 August 2018     
*Corresponding Author(s):  CHEN CHEN     E-mail:  chenchency99@163.com

Cite this article: 

Li-Yuan Guo, San-Yuan Zhang, Chen Chen, Hao-Xia Zeng, Feng-Yan Li, Qiu-Xiang Xu. Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites. European Journal of Gynaecological Oncology, 2018, 39(4): 615-620.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4178.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I4/615

[1] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[2] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[3] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[4] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[5] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
[6] V. Pažin, A. Dobrosavljevic, L. Nejkovic. Primary fallopian tube carcinoma – case report[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 163-165.
[7] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[8] Jing Zhao, Xue Dong, Qing-cui Liu, Qun Lu. Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 769-772.
[9] K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.
[10] Jun Dai, Peishu Liu, Yangyun Liu, Wei Cai. An experimental study of cyclinD1 expression in human epithelial ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 247-252.
[11] B.D. de-la-Noval, M.D. Diestro Tejeda, L. Yébenes, I. Zapardiel, A. Hernández Gutiérrez, J. De-Santiago García. Recurrent endometriosis following tibolone hormone replacement therapy after mucinous ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 310-313.
[12] J.M. Mañé, B. Calvo, U. Aresti, S. Carrera, A. Sancho, E. Azkona, I. Marrodán, I. Ugalde, I. Rubio, G. López-Vivanco. Epithelial ovarian cancer and primary peritoneal carcinomatosis in the elderly: what is our clinical practice?[J]. European Journal of Gynaecological Oncology, 2017, 38(5): 695-699.
[13] F. Celik, M. Kose. Increased neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios can be used to distinguish ovarian masses[J]. European Journal of Gynaecological Oncology, 2017, 38(5): 720-723.
[14] A. Stiekema, C.A.R. Lok, M. v Beurden, S.B. Coffelt, W.J. van Driel, G.G. Kenter, C.M. Korse. Serial measurements of serum human epididymal protein 4 in patients at risk for ovarian cancer[J]. European Journal of Gynaecological Oncology, 2017, 38(5): 750-755.
[15] A. Bastani, A. Asghary, M.H. Heidari, F. Karimi-Busheri. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2017, 38(3): 418-424.
No Suggested Reading articles found!